TEMODAR® (Temozolomide) Uses and Advantages

TEMODAR® is a prescription medication developed by Merck & Co., Inc., used in the treatment of certain types of brain tumors. Its active ingredient, temozolomide, is an oral chemotherapy drug that is also available as an intravenous (IV) formulation. TEMODAR® plays a crucial role in managing glioblastoma multiforme and other brain tumors, offering hope for patients battling these challenging conditions. Here, we will provide a detailed overview of TEMODAR®’s formulation, uses, advantages, side effects, dosage guidelines, precautionary measures, and pricing in the UK and USA.

Formulation of TEMODAR® (Temozolomide)

TEMODAR® is a vailable in two forms:

1. Capsules: The oral formulation of TEMODAR® comes in various strengths including 5 mg, 20 mg, 100 mg, 140 mg, and 180 mg. These capsules are taken by mouth and are typically used in the outpatient setting.
2. Injection: The intravenous form is available in a 100 mg vial, which is administered by healthcare professionals in a clinical setting.

Uses of TEMODAR® (Temozolomide)

TEMODAR® is primarily used to treat:

1. Glioblastoma Multiforme (GBM): An aggressive form of brain cancer. TEMODAR® is often used in conjunction with radiation therapy following initial surgery.
2. Anaplastic Astrocytoma: A type of brain tumor that TEMODAR® can treat after disease progression or as part of a combination treatment regimen.

Advantages of TEMODAR®(Temozolomide)

Oral and IV Administration: TEMODAR® offers flexibility in treatment settings. The oral form allows for outpatient treatment, while the IV form can be used in more controlled settings.

1. Enhanced Efficacy: When used in combination with radiation therapy, TEMODAR® has been shown to improve survival rates and extend progression-free survival in patients with GBM.
2. Convenience: For many patients, the oral form of TEMODAR® can be easier to administer compared to frequent hospital visits for IV chemotherapy.

Side Effects of TEMODAR®(Temozolomide)

While TEMODAR® is effective, it can also cause side effects. Common side effects include:

• Nausea and Vomiting
• Loss of Appetite
• Fatigue
• Headache
• Constipation

Serious side effects may include:

1. Bone Marrow Suppression: This can lead to a decrease in blood cell counts, increasing the risk of infections, anemia, and bleeding.
2. Liver Toxicity: Elevated liver enzymes and liver damage can occur, necessitating regular liver function tests.
3. Infections: Due to its impact on blood cell counts, patients may be more susceptible to infections.

Dosage of TEMODAR®(Temozolomide)

The dosage of TEMODAR® is determined based on the patient’s condition, body surface area, and other individual factors. General dosing guidelines are as follows:

• Glioblastoma Multiforme: The standard regimen involves 75 mg/m² daily for 42 days, usually taken in combination with radiation therapy, followed by a rest period. After this, treatment may continue with 150-200 mg/m² daily for 5 days every 28 days, up to a maximum of 6 cycles.
• Anaplastic Astrocytoma: Treatment typically starts with 150-200 mg/m² daily for 5 days every 28 days, similar to the regimen for GBM.

Precautionary Measures 

Before starting TEMODAR®, consider the following precautionary measures:

• Bone Marrow Function: Regular blood tests are essential to monitor for bone marrow suppression.
• Liver Function: Periodic liver function tests are recommended due to potential liver toxicity.
• Pregnancy and Breastfeeding: TEMODAR® is classified as a Category D drug (positive evidence of risk) during pregnancy and should be avoided unless absolutely necessary. It is also not recommended for breastfeeding.
• Vaccinations: Avoid live vaccines during treatment due to the risk of reduced immune function.
• Drug Interactions: Inform your healthcare provider of all other medications being taken, as certain drugs can interact with TEMODAR® and affect its efficacy or increase side effects.

Year of Invention of TEMODAR®(Temozolomide)

TEMODAR® was developed and first approved for use in 1999. It represents a significant advancement in chemotherapy for brain tumors and has been widely adopted as a standard treatment for glioblastoma multiforme and anaplastic astrocytoma.

Company Information

TEMODAR® is manufactured by Merck & Co., Inc., a renowned global healthcare company. Merck, established in 1891, is headquartered in Kenilworth, New Jersey, and is known for its extensive portfolio of innovative medicines and vaccines. The company is dedicated to advancing treatments and improving patient outcomes worldwide.

Price in USA and UK of TEMODAR®(Temozolomide)

The cost of TEMODAR® can vary based on the formulation, dosage, and location. Here is a general guide to pricing:

• USA: The price for TEMODAR® capsules typically ranges from $2,000 to $3,000 for a one-month supply, depending on dosage and insurance coverage. The IV formulation is generally priced higher and may cost upwards of $4,000 per vial.
• UK: In the UK, TEMODAR® is available through the NHS, and the cost to patients may be subject to prescription charges. The private cost for TEMODAR® capsules can range from £1,500 to £2,500 per month.

Conclusion

TEMODAR® (temozolomide) is a vital medication in the treatment of aggressive brain tumors such as glioblastoma multiforme and anaplastic astrocytoma. Its dual availability in oral and IV formulations provides flexibility in treatment, while its efficacy in combination with radiation therapy offers improved survival outcomes for patients. Understanding the potential side effects and following precautionary measures are crucial for optimizing treatment and managing risks. With its significant role in oncology, TEMODAR® continues to be a critical tool in the fight against brain cancer.